Expertise in
44
conditions

Dr. Filip J. Janku

Oncology
UT MD Anderson Cancer Center
210 Ashville Ave # 408, 
Cary, NC 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
44
conditions
UT MD Anderson Cancer Center
210 Ashville Ave # 408, 
Cary, NC 

Overview

Filip Janku is an Oncologist practicing medicine in Cary, North Carolina.

Dr. Janku is highly rated in 44 conditions, according to our data. His clinical expertise encompasses PIK3CA-Related Overgrowth Spectrum, Adult Soft Tissue Sarcoma, Colorectal Cancer, Gastrointestinal Stromal Tumor, and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 279 peer reviewed articles and participating in 30 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in TX

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

UT MD Anderson Cancer Center
210 Ashville Ave # 408, Cary, NC 27518

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

30 Clinical Trials

First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors
First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: August 15, 2025
Intervention Type: Drug
Study Drugs: BCA101, Pembrolizumab
Study Phase: Phase 1
A Phase I Trial of Sirolimus or Everolimus or Temsirolimus (mTOR Inhibitor) and Vorinostat (Histone Deacetylase Inhibitor) in Patients With Advanced Cancer
A Phase I Trial of Sirolimus or Everolimus or Temsirolimus (mTOR Inhibitor) and Vorinostat (Histone Deacetylase Inhibitor) in Patients With Advanced Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2026
Intervention Type: Drug
Study Drugs: Sirolimus, Vorinostat, Everolimus, Temsirolimus
Study Phase: Phase 1
A Phase 1/2a, Dose-escalation Study of FF-10502-01 for the Treatment of Advanced Solid Tumors and Lymphomas
A Phase 1/2a, Dose-escalation Study of FF-10502-01 for the Treatment of Advanced Solid Tumors and Lymphomas
Enrollment Status: Completed
Publish Date: April 23, 2026
Intervention Type: Drug
Study Drug: FF-10502-01
Study Phase: Phase 1/Phase 2
A Phase Ib Investigation of Pembrolizumab in Combination With Intratumoral Injection of Clostridium Novyi-NT in Patients With Treatment-Refractory Solid Tumors
A Phase Ib Investigation of Pembrolizumab in Combination With Intratumoral Injection of Clostridium Novyi-NT in Patients With Treatment-Refractory Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: April 16, 2026
Intervention Type: Drug, Biological
Study Drugs: Pembrolizumab, Clostridium Novyi-NT, Doxycycline
Study Phase: Phase 1
A Multicenter, Open-Label, Phase I Study Evaluating the Safety and Tolerability of HMPL-306 in Subjects With Locally Advanced or Metastatic Solid Tumors With IDH Mutations
A Multicenter, Open-Label, Phase I Study Evaluating the Safety and Tolerability of HMPL-306 in Subjects With Locally Advanced or Metastatic Solid Tumors With IDH Mutations
Enrollment Status: Terminated
Publish Date: March 27, 2026
Intervention Type: Drug
Study Drug: HMPL-306
Study Phase: Phase 1
A Phase 2 Study of Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Patients With Percutaneously Accessible Lesions With Advanced Melanoma Refractory to PD-1/PD-L1 Inhibitor Therapy.
A Phase 2 Study of Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Patients With Percutaneously Accessible Lesions With Advanced Melanoma Refractory to PD-1/PD-L1 Inhibitor Therapy.
Enrollment Status: Completed
Publish Date: November 20, 2025
Intervention Type: Combination product
Study Phase: Phase 2
A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies
A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: November 14, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study of ERK1/2 Inhibitor JSI-1187 Administered as Monotherapy and in Combination With Dabrafenib for the Treatment of Advanced Solid Tumors With MAPK Pathway Mutations
A Phase 1 Study of ERK1/2 Inhibitor JSI-1187 Administered as Monotherapy and in Combination With Dabrafenib for the Treatment of Advanced Solid Tumors With MAPK Pathway Mutations
Enrollment Status: Suspended
Publish Date: September 03, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: July 03, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 2 Basket Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination With Pembrolizumab in Patients With Advanced Solid Cancers
A Phase 2 Basket Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination With Pembrolizumab in Patients With Advanced Solid Cancers
Enrollment Status: Terminated
Publish Date: May 16, 2025
Intervention Type: Drug, Biological
Study Phase: Phase 2
View 9 Less Clinical Trials

279 Total Publications

PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
Journal: JCO precision oncology
Published: August 27, 2025
Similar Doctors
Expertise in
29
conditions
Expertise in
29
conditions
Referral may be required

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (0.1 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Anthony Conley is an Oncologist practicing medicine in Cary, North Carolina. Dr. Conley is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Chondrosarcoma, Alveolar Soft Part Sarcoma, Liposarcoma, and Salpingo-Oophorectomy.

Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (0.1 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances

Alessandra Ferrajoli is an Oncologist practicing medicine in Cary, North Carolina. Dr. Ferrajoli is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Leukemia, Small Lymphocytic Lymphoma (SLL), and Bone Marrow Aspiration.

Expertise in
19
conditions
Expertise in
19
conditions
Referral may be required

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (0.1 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances

Michelle Fanale is an Oncologist practicing medicine in Cary, North Carolina. Dr. Fanale is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, T-Cell Lymphoma, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Filip J. Janku

How do I make an appointment with Dr. Filip J. Janku?

You can book an appointment with Dr. Filip J. Janku by calling their office at 713-792-6161. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Filip J. Janku a top-rated expert for PIK3CA-Related Overgrowth Spectrum?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Filip J. Janku is classified as an Elite expert for PIK3CA-Related Overgrowth Spectrum, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Filip J. Janku specialize in?

While Dr. Filip J. Janku is a Oncology, they have specific expertise in PIK3CA-Related Overgrowth Spectrum, Adult Soft Tissue Sarcoma, and Colorectal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Filip J. Janku participate in research or clinical trials?

Yes. Dr. Filip J. Janku has published 279 articles and abstracts on conditions like PIK3CA-Related Overgrowth Spectrum. You can view a list of Dr. Filip J. Janku's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Janku's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 32 Advanced Conditions
View All 57 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile